Listing of Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-9. (canceled).

Claim 10. (currently amended) A mutant *ras* peptide comprising:

an amino acid sequence of at least 8 ~~to no more than 13~~ amino acids, ~~wherein said amino acid~~ **from the** sequence ~~comprises~~ **consisting of** Xaa_1 Leu Xaa_2 Val Val Gly Ala Xaa_3 Gly Val **Gly Lys Ser** (SEQ ID NO:~~14~~ **15**);

wherein Xaa_1 is the amino acid lysine or tyrosine;

wherein Xaa_2 is an amino acid;

wherein Xaa_3 is selected from the group consisting of aspartic acid, valine, cysteine, alanine, arginine, ~~or~~ **and** serine;

wherein when Xaa_2 is valine, Xaa_1 is tyrosine

and said peptide elicits a peptide-specific human $CD8^+$ cytotoxic T lymphocyte immune response.

Claim 11. (currently amended): The mutant *ras* peptide of claim 10 **or 72**, wherein the peptide comprises an amino acid sequence of 13 amino acids.

Claim 12. (currently amended): The mutant *ras* peptide of claim 10 **or 72**, wherein the peptide comprises an amino acid sequence of 10 amino acids.

Claim 13. (currently amended): The mutant *ras* peptide of claim 10 **or 72**, wherein Xaa_1 is tyrosine.

Claim 14. (currently amended): The mutant *ras* peptide of claim 10 **or 72**, wherein Xaa_2 is selected from the group consisting of valine, tryptophan, leucine, tyrosine, and phenylalanine.

Claim 15. (currently amended): The mutant *ras* peptide of claim 10 **or 72** wherein Xaa_1 is tyrosine, and Xaa_3 is aspartic acid.

Claims 16-24. (canceled).

Claim 25. (currently amended): A mutant *ras* peptide-carrier molecule conjugate comprising the mutant *ras* peptide claim 10 **or 72** and a carrier molecule, wherein said carrier molecule enhances the immunogenicity of the peptide.

Claim 26. (canceled).

Claim 27. (**currently amended** ~~previously presented~~) An immunogen for eliciting a mutant *ras* peptide-specific human $CD8^+$ cytotoxic T lymphocyte immune response comprising a mutant *ras* peptide of claim 10 **or 72**, wherein the immunogen elicits a mutant *ras* peptide-specific human $CD8^+$ cytotoxic T lymphocyte immune response.

Claims 28-31. (canceled).

Claim 32. (currently **amended** ~~ammended~~) A pharmaceutical composition comprising the mutant *ras* peptide of claim 10 **or 72** and a pharmaceutically acceptable carrier.

Claim 33. (previously presented) The pharmaceutical composition of claim 32, further comprising a biological response modifier.

Claim 34. (previously presented) The pharmaceutical composition of claim 32, further comprising a liposome formulation, an antigen presenting cell, or an adjuvant comprising mycobacterial cell wall skeleton and monophosphoryl lipid A.

Claims 35-65. (canceled).

Claim 66. (previously presented) The mutant *ras* peptide-carrier molecule conjugate of claim 25, wherein the carrier molecule is selected from the group consisting of influenza peptide, tetanus toxoid-CD4 epitope, Pseudomonas exotoxin A, and poly-L-lysine.

Claim 67. (previously presented) The mutant *ras* peptide-carrier molecule conjugate of claim 25, wherein the carrier molecule is tetanus toxoid.

Claim 68. (previously presented) The pharmaceutical composition of claim 33, wherein the biological response modifier is interleukin 2.

Claim 69. (canceled).

Claim 70. (previously presented) The pharmaceutical composition of claim 32, further comprising interleukin 2, interleukin 6, interleukin 12, interferon, tumor necrosis factor, GM-CSF, β2-microglobulin, or combinations thereof.

Claim 71. (previously presented) The pharmaceutical composition of claim 33, further comprising a liposome formulation, an antigen presenting cell, or an adjuvant comprising mycobacterial cell wall skeleton and monophosphoryl lipid A.

Claim 72. (new) A mutant *ras* peptide comprising:

an amino acid sequence of at least 8 amino acids, wherein said amino acid from the sequence comprises consisting of Tyr Xaa_1 Leu Xaa_2 Val Val Gly Ala Xaa_3 Gly Val Gly Lys Ser (SEQ ID NO:16);

wherein Xaa_1 is the amino acid lysine or tyrosine;

wherein Xaa_2 is an amino acid;

wherein Xaa_3 is selected from the group consisting of aspartic acid, valine, cysteine, alanine, arginine, or and serine;

wherein when Xaa_2 is valine, Xaa_1 is tyrosine

and said peptide elicits a peptide-specific human $CD8^+$ cytotoxic T lymphocyte immune response.

Applicants do not believe that any filing or extension fees are required. In the event that this is not correct, Applicants request an extension of time and authorize the Commissioner to charge the undersigned's Deposit Account No. 08-1641.

Respectfully submitted,

Date: June 9, 2005

By Patricia D. Granados

Customer No. 44991
HELLER EHRMAN LLP
1717 Rhode Island Avenue NW
Washington, DC 20036-3001
Telephone: (202) 912-2000
Facsimile: (202) 912-2020

Patricia D. Granados
Agent for Applicants
Registration No. 33,683